I Flow Corp

I-Flow Corp. said Monday that it has retained investment banker Wedbush Morgan Securities to help identify and evaluate potential acquisitions and strategic partnerships. I-Flow said it plans to expand in the ambulatory infusion pump market and expects acquisitions and strategic partnerships to play an important role in its growth. I-Flow designs, develops and markets ambulatory infusion systems.

I-Flow Corp. said Monday that it expects third-quarter revenue and operating income to be "significantly" improved from results a year ago. The company, which designs and develops ambulatory infusion systems, said it expects revenue of about $4 million, up from $2.6 million a year ago, while operating income should climb to 6 cents per share from 4 cents per share. The income for the quarter ended Sept.

I-Flow Corp., which posted a profitable quarter and first six months, said Thursday that it expects a third-quarter loss because of a write-off and expenses totaling $5.6 million. The developer of ambulatory infusion systems said that it will write off $5 million for research and development costs and will incur $600,000 in additional expenses related to its acquisition last month of Block Medical operations.

I-Flow Corp. said Tuesday it has completed its acquisition of Block Medical Inc., a maker of portable infusion devices, from Hillenbrand Industries Inc. for stock, warrants and $15 million in cash. Block Medical, which is headquartered in San Diego and has a manufacturing facility in northern Mexico, had revenue of approximately $13.5 million for the fiscal year ended Dec. 2.

I-Flow Corp. said Tuesday that it has reached a definitive agreement to acquire Hillenbrand Industries Inc.'s Block Medical unit, a San Diego manufacturer of portable infusion devices. I-Flow will pay about $15 million in cash, $2 million of I-Flow common stock, and five-year, non-callable warrants to acquire 250,000 I-Flow common shares for the stock's price on the closing date. Block Medical had revenue of about $13.5 million in 1995.

I-Flow Corp. expanded its agreement with Fresenius AG, a German distributor, to sell its ambulatory infusion products in 22 European countries. The agreement includes an initial licensing fee payment of $300,000 and minimum purchase requirements totaling $13.3 million over five years, I-Flow said. The original agreement allowed Fresenius to sell the products in only Germany, Switzerland and Austria, I-Flow said.